Home

Insights

Sun Pharmaceuticals Industries Ltd P/E Ratio

Sun Pharmaceuticals Industries Ltd P/E Ratio

download
stocks purchased

₹ 1.0 Cr

Volume transacted

stocks purchased

6.4 K

stocks traded

Image

Sun Pharmaceuticals Industries Ltd

NSE: SUNPHARMA

PE

39.3

Last updated : 21 May 05:41 AM

Key Highlights

    The P/E Ratio of Sun Pharmaceuticals Industries Ltd is 39.3 as of 21 May 05:41 AM .a1#The P/E Ratio of Sun Pharmaceuticals Industries Ltd changed from 43.1 on March 2019 to 27.8 on March 2023 . This represents a CAGR of -8.40% over 5 years. a1#The Latest Trading Price of Sun Pharmaceuticals Industries Ltd is ₹ 1535 as of 21 May 09:09 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 27.2. The PE Ratio of Finance industry is 13.6. The PE Ratio of IT - Software industry is 27.9. The PE Ratio of Pharmaceuticals industry is 27.7. The PE Ratio of Retail industry is 94.8. The PE Ratio of Textiles industry is 21.1. In 2023a1#The Market Cap of Sun Pharmaceuticals Industries Ltd changed from ₹ 114988 crore on March 2019 to ₹ 235878 crore on March 2023 . This represents a CAGR of 15.45% over 5 years. a1#The Revenue of Sun Pharmaceuticals Industries Ltd changed from ₹ 10763 crore to ₹ 12630 crore over 7 quarters. This represents a CAGR of 9.57% a1#The EBITDA of Sun Pharmaceuticals Industries Ltd changed from ₹ 2886 crore to ₹ 3657 crore over 7 quarters. This represents a CAGR of 14.48% a1#The Net Profit of Sun Pharmaceuticals Industries Ltd changed from ₹ 2095 crore to ₹ 2568 crore over 7 quarters. This represents a CAGR of 12.31% a1#The Dividend Payout of Sun Pharmaceuticals Industries Ltd changed from 80.8 % on March 2019 to 163.2 % on March 2023 . This represents a CAGR of 15.10% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1943.1
Mar '2022.5
Mar '2149.4
Mar '2267.1
Mar '2327.8

Fundamental Metrics

Market Cap

367,290 Cr

EPS

39.1

P/E Ratio (TTM) *

39.3

P/B Ratio (TTM) *

6.2

Day’s High

1535.15

Day’s Low

1535.15

DTE *

0.0

ROE *

14.3

52 Week High

1638.7

52 Week Low

922.55

ROCE *

16.5

* All values are consolidated

* All values are consolidated

Image

Sun Pharmaceuticals Industries Ltd

NSE: SUNPHARMA

PRICE

1535.15

4.35(0.28%)

stock direction

Last updated : 21 May 09:09

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Sun Pharmaceuticals Industries Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Sun Pharmaceuticals Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value

Market Value

3,68,598

Asset Value

35,899

9.3 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

8,906 Cr

39.3 X

PE Ratio

Market Cap

₹368597Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

8,906 Cr

39.3 X

PE Ratio

Market Cap

₹368597Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Sun Pharmaceuticals Industries Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Sun Pharmaceuticals Industries Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Sun Pharmaceuticals Industries Ltd's Share Price stands at 1535.15. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-05-21T09:09:00 is 39.1. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 1535.15/ 39.1= 39.29.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Sun Pharmaceuticals Industries Ltd's stock is trading at approximately 39.29 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Sun Pharmaceuticals Industries Ltd’s PE Ratio (BSE: SUNPHARMA)

    The Price-to-Earnings (PE) ratio, used to assess Sun Pharmaceuticals Industries Ltd's stock (BSE: SUNPHARMA), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '19114988
Mar '2084505
Mar '21143384
Mar '22219491
Mar '23235879

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '2210764
Sep '2211038
Dec '2211415
Mar '2211304
Jun '2312145
Sep '2312486
Dec '2312631

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '222887
Sep '223042
Dec '223178
Mar '223004
Jun '233213
Sep '233473
Dec '233657

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '222096
Sep '222260
Dec '222188
Mar '222017
Jun '232013
Sep '232401
Dec '232568

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1981
Mar '2030
Mar '21214
Mar '22-2400
Mar '23163

* All values are a in %

About Sun Pharmaceuticals Industries Ltd

About Sun Pharmaceuticals Industries Ltd

    Sun Pharmaceutical Industries Limited including its subsidiaries and associates (Sun Pharma) is the fourth largest global specialty generic company that is ranked No. In the year 1998, the company established their first research center, SPARC and this created the base for strong product and process development that enabled growth in the subsequent years. Also, the company acquired equity stake in Gujarat Lyka Organics Ltd., a manufacturer of Cephalexin Active with a USFDA approval for the intermediate, 7ADCA. In the year 1998, the company acquired a basket of products, including several respiratory/asthma brands acquired from Natco Pharma. During the year, the company completed the construction at a formulation manufacturing site at Jammu. In June 14, 2011, Caraco Pharmaceutical Laboratories Ltd (Caroco) merged with a subsidiary of the company. The Company announces USFDA approval for generic Prevacid, generic DoxilAr and generic DepoAr-Testosterone Injection. The acquired brands will be marketed by a reliable and established local marketing partner under the Sun Pharma label. The purpose of the buyback is to return surplus funds to the equity shareholders and thereby, enhancing the overall returns to shareholders. On 18 July 2016, Sun Pharma and Sun Pharma Advanced Research Company Ltd. (SPARC) announced a licensing arrangement for SPARC's ELEPSIA XR (Levetiracetam Extended Release tablets). Sun Pharma will be eligible to receive development and regulatory milestone payments and, additionally, sales milestone payments and royalties on net sales. It was the first branded product launched by the company in the USA following its focus on Specialty Business. On 22 December 2016, Sun Pharma announced its plans to acquire a branded oncology product Odomzo from Novartis. The agreement was signed for an upfront payment of US$ 175 million and additional milestone payments. The USFDA had taken action against the Mohali facility in 2013 when it ordered the facility to be fully subject to Ranbaxy's Consent Decree of Permanent Injunction. Sun Pharma will provide drug molecules to NIV for testing against Zika, Chikungunya and Dengue in model systems. These RTA bags will provide greater safety, by preventing problems of over-dosing or under-dosing and eliminating contamination risk. In August 2019, Sun Pharma granted an exclusive license to a subsidiary of China Medical System Holdings Ltd. (CMS) to develop and commercialise seven generic products in Mainland China. In November 2019, Sun Pharma entered into a licensing agreement with AstraZeneca UK Ltd. (AstraZeneca) to introduce certain novel ready to use (RTU) infusion oncology products in China. It initiated Phase-2 clinical trials for a potential oral treatment for atopic dermatitis and moderate to severe plaque psoriasis.

Sun Pharmaceuticals Industries Ltd News Hub

News

Sun Pharmaceuticals Industries to hold board meeting

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Compan...

Read more

13 May 2024 17:24

News

Sun Pharmaceuticals Industries Ltd slips for fifth straight session

Sun Pharmaceuticals Industries Ltd dropped for a fifth straight session today. The stock i...

Read more

08 Apr 2024 13:35

News

Sun Pharmaceuticals Industries Ltd spurts 2.46%, rises for third straight session

Sun Pharmaceuticals Industries Ltd rose for a third straight session today. The stock is q...

Read more

22 Mar 2024 13:05

News

Sun Pharma receives nod to launch Winlevi� in Australia

Sun Pharmaceutical Industries announced that the Australian Therapeutic Goods Administrati...

Read more

19 Mar 2024 09:32

News

Sun Pharmaceuticals Industries Ltd soars 0.82%, up for fifth straight session

Sun Pharmaceuticals Industries Ltd gained for a fifth straight session today. The stock is...

Read more

11 Mar 2024 13:00

News

Sun Pharmaceuticals Industries Ltd spurts 0.04%, gains for five straight sessions

Sun Pharmaceuticals Industries Ltd rose for a fifth straight session today. The stock is q...

Read more

22 Feb 2024 13:00

Product Composition by Percentage (Revenue)

Document

Annual Reports

Annual Report 2023

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Feb 2024

Transcript

Jan 2024

PPT

Nov 2023

Transcript

Sep 2023

PPT

May 2023

Transcript

Apr 2023

PPT

Nov 2022

Transcript

Sep 2022

PPT

Aug 2022

Transcript

June 2022

Transcript

Mar 2022

PPT

Feb 2022

Transcript

Nov 2021

Transcript

Aug 2021

Transcript

June 2021

Transcript

Jan 2021

Transcript

Oct 2020

Transcript

Feb 2024

Transcript

Jan 2024

PPT

Nov 2023

Transcript

Sep 2023

PPT

May 2023

Transcript

Apr 2023

PPT

Nov 2022

Transcript

Sep 2022

PPT

Aug 2022

Transcript

June 2022

Transcript

Mar 2022

PPT

Feb 2022

Transcript

Nov 2021

Transcript

Aug 2021

Transcript

June 2021

Transcript

Jan 2021

Transcript

Oct 2020

Transcript

FAQs for PE of Sun Pharmaceuticals Industries Ltd

What is Sun Pharmaceuticals Industries Ltd current share price?

The current market price of Sun Pharmaceuticals Industries Ltd as of May 21, 2024 is ₹1535.15.

Is Sun Pharmaceuticals Industries Ltd a good investment?

As per BlinkX Score Sun Pharmaceuticals Industries Ltd scores 48 in Revenue, 13 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Sun Pharmaceuticals Industries Ltd's total net assets?

According to Sun Pharmaceuticals Industries Ltd's most recent financial filings, the company's net assets total ₹35898.7 Cr.

Is Sun Pharmaceuticals Industries Ltd making a profit or loss?

Sun Pharmaceuticals Industries Ltd's net Profit as of May 21, 2024 is close to ₹8,906 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199